These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Clinical preventive medicine in cancer diagnosis--proposal for a new cancer diagnostic system in an aging society]. Ishimori A Rinsho Byori; 1993 Jun; 41(6):617-24. PubMed ID: 8361026 [TBL] [Abstract][Full Text] [Related]
3. [Current advancement of assay of tumor markers and the perspective in future]. Kawamura T Nihon Rinsho; 1996 Jun; 54(6):1642-8. PubMed ID: 8691623 [TBL] [Abstract][Full Text] [Related]
4. [An evaluation of tumor markers and risk factors in mass screening for various cancers]. Fujimoto H; Sasaki Y; Kawamura T; Ishimori A; Yanagiya T; Saita T Rinsho Byori; 1993 Jun; 41(6):642-8. PubMed ID: 8361030 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic markers for early detection of ovarian cancer. Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665 [TBL] [Abstract][Full Text] [Related]
6. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis]. Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326 [TBL] [Abstract][Full Text] [Related]
7. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549 [TBL] [Abstract][Full Text] [Related]
8. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of four serological tumor markers for the detection of breast cancer. Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928 [TBL] [Abstract][Full Text] [Related]
10. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma. Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138 [TBL] [Abstract][Full Text] [Related]
11. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Sun Z; Fu X; Zhang L; Yang X; Liu F; Hu G Anticancer Res; 2004; 24(2C):1159-65. PubMed ID: 15154641 [TBL] [Abstract][Full Text] [Related]
12. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Griesenberg D; Nürnberg R; Bahlo M; Klapdor R Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173 [TBL] [Abstract][Full Text] [Related]
13. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer]. Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796 [TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
15. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients]. Grotowski M; Maruszyński M; Piechota W Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841 [TBL] [Abstract][Full Text] [Related]
16. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798 [TBL] [Abstract][Full Text] [Related]
18. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]. Pan QR; Zhang X; Xu ZF; Zheng S Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076 [TBL] [Abstract][Full Text] [Related]
19. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532 [TBL] [Abstract][Full Text] [Related]
20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Jiang XT; Tao HQ; Zou SC Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]